NCT00820560View on ClinicalTrials.gov

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Solid Tumors and Hematologic Malignancy

Interventions

DRUG

INCB007839

INCB007839 100 or 200 mg/dose as IR capsules

Trial Locations (4)

Unknown

Aurora

Baltimore

Philadelphia

Nashville

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY

NCT00820560 - Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter